# The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

Study · id `cardio:ct-nct03142152` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03142152](<https://clinicaltrials.gov/study/NCT03142152>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03142152

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT03142152. Randomized; double masking; primary purpose treatment. Start 2018-01-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT03142152, source copy `cardio:ctgov-nct03142152-2026-04-13`, retrieved 2026-10-26)
- Started: 2018-01-01 (actual) (ClinicalTrials.gov record NCT03142152, source copy `cardio:ctgov-nct03142152-2026-04-13`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT03142152, source copy `cardio:ctgov-nct03142152-2026-04-13`, retrieved 2026-10-26)
- Completion: 2030-12-31 (anticipated) (ClinicalTrials.gov record NCT03142152, source copy `cardio:ctgov-nct03142152-2026-04-13`, retrieved 2026-10-26)
- Countries: United States; Canada; France; Greece; Italy; Poland; Spain; United Kingdom (ClinicalTrials.gov record NCT03142152, source copy `cardio:ctgov-nct03142152-2026-04-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03142152-2026-04-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
- Condition: Functional Mitral Regurgitation
- Condition: Heart Failure
- Condition: Mitral Valve Insufficiency
- Condition: Heart Diseases
- Condition: Cardiovascular Diseases
- Condition: Heart Valve Diseases
- Intervention (Device): Carillon Mitral Contour System
- Intervention (Other): Guideline Directed Heart Failure Medication
- Lead sponsor: Cardiac Dimensions, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Mitral regurgitation (`cardio:mitral-regurgitation`)

## Provenance

Content hash: 8bcf4d3df89ee19f1188202211aa393e56806e32f16c393775d02b7651c771ad
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
